Overview

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Arthrosi Therapeutics
Collaborator:
Iqvia Pty Ltd